NCT00915785已完成2 期
Pilot Study of 5 Azacytidine in the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukaemia With High-risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- The rate of haematological and cytogenetic response in patients with MDS/AML with a chromosome 7 abnormality either alone or as part of a complex clone
研究概览
简要总结
The purpose of this study is to assess the hematological and cytogenetic responses with 5 azacytidine in patients over 55 years of age with MDS/AML due to chromosome 7 abnormalities and to assess the hematological and cytogenetic response rates in patients with relapsed AML and chromosome 7 abnormality.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Abnormalities to chromosome 7, including monosomy 7 either alone or as part of a complex clone.
- •Be > 55 years of age; younger if first or subsequent relapse in patient less < 55 years but with a chromosome 7 abnormality alone or as part of a complex clone.
- •Have an International Prognostic Scoring System (IPSS) score of INT 1.5 and a diagnosis of RAEB or RAEB-T per French-American-British (FAB) classification criteria or a diagnosis of Myelodysplastic CMMoL per modified FAB criteria meeting the following:
- •Monocytosis in peripheral blood > 1x109/L;
- •Dysplasia in one or more myeloid cell lines;
- •10% to 29% blasts in the BM;
- •White blood cell (WBC) < 13,000 x109/L;
- •Have a life expectancy of at least 3 months;
- •Have an Eastern Cooperative Oncology Group (ECOG) Performance Status Grade of 0-
- •Have serum bilirubin levels of at least 1.5 x the upper limit of the normal range for the laboratory (ULN). Higher levels are acceptable if these can be attributed to:
- •active hemolysis (as indicated by positive direct Coombs' testing);
- •decreased or absent haptoglobin level;
- •elevated indirect bilirubin and/or lactate dehydrogenase [LDH]); or
- •ineffective erythropoiesis (as indicated by bone marrow findings).
- •Have serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) levels of at least 2 x ULN.
- •Have serum creatinine levels of at least 1.5 x ULN.
- •Women of childbearing potential may participate, providing they meet the following conditions:
- •must agree to use at least 2 effective contraceptive methods throughout the study and for 3 months following the date of the last dose of study medication;
- •must have a negative serum pregnancy test obtained within 24 hours prior to Day
- •Males with female partners of childbearing potential must agree to use at least 2 effective contraceptive methods throughout the study and should avoid fathering a child for 6 months following the date of the last dose of study medication.
- •Be able to provide written informed consent.
排除标准
- •Prior treatment with azacitidine.
- •Diagnosis of malignant disease within the previous 12 months (excluding basal cell carcinoma with no complications).
- •Diagnosis of metastatic disease.
- •Previous diagnosis of hepatic tumors.
- •Radiation therapy, chemotherapy, or cytotoxic therapy, given to treat conditions other than MDS/AML and administered within the previous 12 months prior to the first day of treatment (Day 1).
- •Known or suspected hypersensitivity to azacitidine or mannitol.
- •Prior or active disease that, in the opinion of the Investigator, may interfere with the procedures or evaluations to be conducted in the study.
- •Serious medical illness likely to limit survival to under or equal to 12 months after screening or likely to prevent granting of informed consent (e.g., history of severe congestive heart failure, clinically unstable cardiac disease, or pulmonary disease).
- •Psychiatric illness that would prevent granting of informed consent;
- •Treatment with erythropoietin or myeloid growth factors (granulocyte colony-stimulating factor [G-CSF] or granulocyte-macrophage colony-stimulating factor [GM-CSF]) during the previous 21 days prior to Day
- •Treatment with androgenic hormones during the previous 14 days prior to Day
- •Active viral infection with known human immunodeficiency virus (HIV) or viral hepatitis type B or C.
- •Treatment with other investigational drugs within the previous 30 days prior to Day 1, or ongoing adverse events from previous treatment with investigational drugs, regardless of the time period.
研究组 & 干预措施
5 azacytidine
Experimental
干预措施: 5 azacytidine (Drug)
结局指标
主要结局
The rate of haematological and cytogenetic response in patients with MDS/AML with a chromosome 7 abnormality either alone or as part of a complex clone
时间窗: Blood - Weekly for first 2 cycles and then fortnightly. Bone marrow - Day 7 of first cycle and then 16 weekly thereafter or ealier if clinically indicated.
次要结局
- Time to relapse after complete remission (CR) or partial remission (PR), or disease progression (per IWG criteria), censored at death(Blood - Weekly for first 2 cycles and then fortnightly. Bone marrow - Day 7 of first cycle and then 16 weekly thereafter or ealier if clinically indicated.)
- Duration of response and duration of improvement(Blood - Weekly for first 2 cycles and then fortnightly. Bone marrow - Day 7 of first cycle and then 16 weekly thereafter or ealier if clinically indicated.)
- Time to AML transformation or death from any cause(Blood - Weekly for first 2 cycles and then fortnightly. Bone marrow - Day 7 of first cycle and then 16 weekly thereafter or ealier if clinically indicated.)
- Additional cytogenetic markers: DNA methylation status, assessment of markers of apoptosis. Change in gene expression and single nucleotide polymorphism profiles.(Baseline, Day 7 of the first treatment cycle and then 16 weekly (or ealier if clinically indicated).)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Pilot study of 5 Azacitidine in the treatment of MDS/AML with high risk (chromosome 7 and/or complex cytogenetic abnormality) - Azacitidine for MDS with high risk cytogeneticsmyelodysplastic syndromes/relapsed Acute myeloid leukaemiaEUCTR2005-003732-22-GBKings College London43
已完成
2 期
Phase II 5-Azacytidine Plus VPA Plus ATRAAcute Myelogenous LeukemiaMyelodysplastic SyndromeNCT00326170M.D. Anderson Cancer Center34
已完成
2 期
5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic SyndromeMyelodysplastic SyndromeNCT00721214Virginia Commonwealth University16
Unknown
1 期
Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral PalsyContractureCerebral PalsyNCT06377085Shirley Ryan AbilityLab27
已完成
1 期
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AMLLymphoblastic Leukemia, Acute, ChildhoodMyelogenous Leukemia, Acute, ChildhoodNCT01861002Therapeutic Advances in Childhood Leukemia Consortium15